Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca increases R&D
January 2008
SHARING OPTIONS:

LONDON—AstraZeneca has raised the goal for research productivity after recently acquiring MedImmune, with plans to have three new drug candidates in late-stage trials by 2010. The long-term target for the MedImmune division, which also includes Cambridge Antibody Technology, reportedly is to submit six new drug applications for approval per year on average. AstraZeneca bought MedImmune, a U.S.-based company, for $15.6 billion to boost its position in the growing biotech drug sector.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.